Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term cell lung-cancer. Found 36 abstracts

no pagination
Zhang Y, Wang J, Xie J, Yang D, Han G, Zhang Y, Fu Q. The assay and clinical significance of serum thymidine kinase 1 in patients with colorectal carcinoma. Eur Surg. 2015 Oct;47(5):248-53.
Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas(dagger). Annals of Oncology. 2013 Jan;24(1):257-63.   PMCID: not NIH funded
Allen AM, Pawlicki T, Dong L, Fourkal E, Buyyounouski M, Cengel K, Plastaras J, Bucci MK, Yock TI, Bonilla L, Price R, Harris EE, Konski AA, Stinseymour M. An evidence based review of proton beam therapy: The report of ASTRO's emerging technology committee. Radiotherapy and Oncology. 2012 Apr;103(1):8-11.   PMCID: not NIH funded
Chen JJ, Sun YL, Tiwari AK, Xiao ZJ, Sodani K, Yang DH, Vispute SG, Jiang WQ, Chen SD, Chen ZS. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. Cancer Science. 2012 Aug;103(8):1531-7.   PMCID: PMC3407321[Available on 2013/8/1]
Levy MH, Adolph MD, Back A, Block S, Codada SN, Dalal S, Deshields TL, Dexter E, Dy SM, Knight SJ, Misra S, Ritchie CS, Sauer TM, Smith T, Spiegel D, Sutton L, Taylor RM, Temel J, Thomas J, Tickoo R, Urba SG, Von Roenn JH, Weems JL, Weinstein SM, Freedman-Cass DA, Bergman MA. Palliative Care. Journal of the National Comprehensive Cancer Network. 2012 Oct;10(10):1284-309.   PMCID: not NIH funded
Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. British Journal of Cancer. 2012 Oct;107(8):1268-76.
Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. British Journal of Cancer. 2012 Oct;107(8):1268-76.   PMCID: PMC3494424
Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M. Myeloid Growth Factors. Journal of the National Comprehensive Cancer Network. 2011 Aug;9(8):914-+.   PMCID: not NIH funded
Heath EI, Blumenschein GR, Cohen RB, LoRusso PM, LoConte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemotherapy and Pharmacology. 2011 Sep;68(3):703-12.   PMCID: not NIH funded
Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ, Shibata D. Expression of the Antiapoptotic Protein Survivin in Colon Cancer. Clinical Colorectal Cancer. 2011 Sep;10(3):188-93.   PMCID: not NIH funded
Kuang YH, Shen T, Chen X, Sodani K, Hopper-Borge E, Tiwari AK, Lee J, Fu LW, Chen ZS. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochemical pharmacology. 2010 Jan;79(2):154-61.   PMCID: PMC2953260
Schnoll RA, Martinez E, Tatum KL, Weber DM, Kuzla N, Glass M, Ridge JA, Langer C, Miyamoto C, Wileyto EP, Leone F. A bupropion smoking cessation clinical trial for cancer patients. Cancer Causes & Control. 2010 Jun;21(6):811-20.   PMCID: NIH funded - needs PMCID
Wong YN, Hamilton O, Egleston B, Salador K, Murphy C, Meropol NJ. Understanding How Out-of-Pocket Expenses, Treatment Value, and Patient Characteristics Influence Treatment Choices. The oncologist. 2010 Jan;15(6):566-76.   PMCID: PMCID: PMC2892556 [Available on 2011/1/1]
Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin DH, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A. Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin. Journal of Thoracic Oncology. 2009 Nov;4(11):1397-403.   PMCID: PMC2941876
de Caceres, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. CANCER RESEARCH. 2006 May;66(10):5021-8.
Engstrom PF, Langer CJ. The Balducci article reviewed. ONCOLOGY-NEW YORK. 2006 Feb;20(2):144-+.
Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK. Progress in chemoprevention drug development: The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - A plan to move forward. CLINICAL CANCER RESEARCH. 2006 Jun;12(12):3661-97.
Bookman MA. Standard treatment in advanced ovarian cancer in 2005: the state of the art. International Journal of Gynecological Cancer. 2005 Nov 03;15:212-20.
Konski A, Feigenberg S, Chow E. Palliative radiation therapy. Seminars in Oncology. 2005 Apr;32(2):156-64.
Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. Journal of Clinical Oncology. 2005 Sep;23(25):6207-19.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term cell lung-cancer

cell lung-cancer chemotherapy breast-cancer Oncology colorectal-cancer randomized-trial therapy metastatic breast-cancer bevacizumab expression trial radiation-therapy ag-013736 prostate-cancer combination receptors paclitaxel elderly-patients survival growth drug-resistance 1990 lkman j-journal of the national cancer institute-v82-p4 abcc10 quality-of-life carboplatin subfamily-b member-1 pharmacokinetics paclitaxel axitinib-docetaxel-capecitabine-solid tumours NSCLC non-hodgkins-lymphoma irradiation chemotherapy-induced 2002 rischilles e-v9-p203 tobacco withdrawal painful bone metastases factor-i Bupropion motexafin gadolinium 871 CP-751 targeting survivin gemcitabine major depression malignant airway-obstruction progression long-term survival high-dose carboplatin controlled-trial colony-stimulating factor pancreatic-cancer placebo-controlled trial surrogate end-points zd1839 iressa stage-iii binding protein-3 prognosis marker Survivin 2008 iorean eg-v26-p2008 therapy-oncology-group care photon gene Apoptosis high-grade dysplasia Multidrug resistance ABCC10 smokers ulcerative-colitis intraperitoneal cisplatin phase-iii trial experience metabolism ovarian cancer messenger-rna topotecan cost of-life care NCCN Guidelines Sunitinib Antiangiogenesis standard therapy tumor-suppressor genes primary peritoneal cancer supportive oncology plus bevacizumab NCCN Clinical Practice Guidelines central anticholinergic syndrome Chemotherapy surgical adjuvant breast induced febrile Colon cancer phase-i low-dose rate symptomatic osseous metastases mrp7 1995 evallier b-v13-p1564 depressive symptoms Cancer patients 1st-line treatment stereotactic radiosurgery inhibitor colorectal carcinoma promoter hypermethylation 871 monoclonal-antibody cp-751 Immunohistochemistry invasive bladder-cancer carcinomas controlled phase-iii soft-tissue sarcomas partitioning analysis rpa phosphodiesterase-5 erectile growth-factor oxaliplatin induced apoptosis willingness-to-pay unrealistic expectations neck-cancer american society human hepatocellular-carcinoma EGFR Tyrosine kinase inhibitor-Lapatinib-Erlotinib-ABC transporters-MRP7 upper-aerodigestive-tract gefitinib growth-factor-receptor tumors cpg-island methylation age bevacizumab angiosarcoma-hemangioendotheliomas-soft tissue sarcoma human colorectal-cancer prognostic-factors epithelial ovarian skull base Solid tumor Phase I aberrant dna methylation external-beam radiotherapy gynecologic-oncology-group myeloid growth ionizing-radiation Radiation therapy Proton beam therapy-Evidence based guidelines chronic hepatitis-c clinical oncology tumor-cells radiotherapy selectivity Figitumumab histone deacetylase inhibition Depression neutropenia sustained-release bupropion fluorouracil
Last updated on Wednesday, July 08, 2020